High throughput Octet BLI applications in early monoclonal antibody discovery

Charles River, Antibody Discovery group, has integrated computational immunology, antibody engineering and phage display technologies into its comprehensive antibody discovery platforms that rapidly deliver antibody hits or optimised variants with a range of affinities, cross-species coverage, and improved drug-like characteristics. Charles River uses label-free biosensors and other bioanalytical assays to support biochemical/biophysical characterisation of biotherapeutic molecules including antibodies.

In this webinar, Christina Pettus, Senior Scientist, Charles River Laboratories, provides insights into how the company incorporates Octet® Bio-Layer Interferometry (BLI) into its monoclonal antibody discovery workflow for discovery campaigns, antibody optimisation, and IgG characterisation. The webinar elaborates on the use of the Octet® BLI for quality control of proteins, high throughput hit screening with crude single chain library clones, blocking/competition assays using crude and purified samples, and kinetic determination of antibody-antigen binding.

Key Learning Objectives from this webinar:
  • • Use of the Octet® BLI platform for ultrahigh throughput hit screening and for off-rate ranking of crude periplasmic extract samples during early antibody discovery.
  • • Octet® BLI applications in reagent quality control including binding interaction studies and rapid antibody quantitation using minimal and crude samples.
  • • Setting up high throughput epitope blocking assays: premix and classical sandwich competition assays with crude periplasmic extracts or purified monoclonal antibodies.
  • How to obtain kinetics measurements of purified monoclonal antibodies in a high throughput manner.
To secure your place, register for FREE now.

 

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free